David Guerrero‐Setas

794 total citations
24 papers, 525 citations indexed

About

David Guerrero‐Setas is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, David Guerrero‐Setas has authored 24 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 9 papers in Oncology and 6 papers in Immunology. Recurrent topics in David Guerrero‐Setas's work include Epigenetics and DNA Methylation (7 papers), Cancer-related gene regulation (6 papers) and Immunotherapy and Immune Responses (4 papers). David Guerrero‐Setas is often cited by papers focused on Epigenetics and DNA Methylation (7 papers), Cancer-related gene regulation (6 papers) and Immunotherapy and Immune Responses (4 papers). David Guerrero‐Setas collaborates with scholars based in Spain, United Kingdom and Belgium. David Guerrero‐Setas's co-authors include David Escors, Grazyna Kochan, Karine Breckpot, Idoia Blanco‐Luquin, Thérèse Liechtenstein, Esperanza Martín‐Sánchez, Rosa Guarch, Enrique Santamaría, Joaquín Fernández‐Irigoyen and Laura Blanco and has published in prestigious journals such as Scientific Reports, International Journal of Molecular Sciences and Oncotarget.

In The Last Decade

David Guerrero‐Setas

22 papers receiving 516 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Guerrero‐Setas Spain 14 250 201 200 96 57 24 525
Marina Gualco Italy 14 354 1.4× 335 1.7× 221 1.1× 56 0.6× 65 1.1× 26 697
Xianfeng Fang China 12 287 1.1× 176 0.9× 211 1.1× 71 0.7× 27 0.5× 19 535
Huda I. Atiya United States 8 202 0.8× 258 1.3× 175 0.9× 114 1.2× 61 1.1× 11 491
Qitai Zhao China 13 334 1.3× 310 1.5× 249 1.2× 152 1.6× 95 1.7× 31 650
Sabrina Carpentier France 9 372 1.5× 225 1.1× 128 0.6× 89 0.9× 69 1.2× 11 573
Jovian Yu United States 11 216 0.9× 232 1.2× 173 0.9× 61 0.6× 64 1.1× 25 506
Sangeeta Kakoti Japan 7 262 1.0× 500 2.5× 243 1.2× 67 0.7× 119 2.1× 12 647
Hussein Shehade United States 7 193 0.8× 172 0.9× 92 0.5× 85 0.9× 31 0.5× 10 378
Emiri Nakazawa Japan 9 182 0.7× 209 1.0× 183 0.9× 51 0.5× 53 0.9× 10 398

Countries citing papers authored by David Guerrero‐Setas

Since Specialization
Citations

This map shows the geographic impact of David Guerrero‐Setas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Guerrero‐Setas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Guerrero‐Setas more than expected).

Fields of papers citing papers by David Guerrero‐Setas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Guerrero‐Setas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Guerrero‐Setas. The network helps show where David Guerrero‐Setas may publish in the future.

Co-authorship network of co-authors of David Guerrero‐Setas

This figure shows the co-authorship network connecting the top 25 collaborators of David Guerrero‐Setas. A scholar is included among the top collaborators of David Guerrero‐Setas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Guerrero‐Setas. David Guerrero‐Setas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Labiano, Ibone, Ana E. Huerta, María Alsina, et al.. (2024). Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinoma. Scientific Reports. 14(1). 16203–16203. 4 indexed citations
2.
Akgül, Mahmut, et al.. (2024). Biphasic papillary (biphasic squamoid alveolar) renal cell carcinoma: a clinicopathologic and molecular study of 17 renal cell carcinomas including 10 papillary adenomas. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 484(3). 441–449. 2 indexed citations
3.
Dorronsoro, María Luisa Gómez, et al.. (2023). ZEB1 hypermethylation is associated with better prognosis in patients with colon cancer. Clinical Epigenetics. 15(1). 193–193.
4.
Fernández‐Irigoyen, Joaquín, Enrique Santamaría, Imanol Arozarena, et al.. (2021). Understanding the Molecular Mechanism of miR-877-3p Could Provide Potential Biomarkers and Therapeutic Targets in Squamous Cell Carcinoma of the Cervix. Cancers. 13(7). 1739–1739. 4 indexed citations
5.
Guerrero‐Setas, David, et al.. (2021). A DNA Methylation-Based Gene Signature Can Predict Triple-Negative Breast Cancer Diagnosis. Biomedicines. 9(10). 1394–1394. 5 indexed citations
6.
Córdoba, Alicia, et al.. (2020). ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 21(3). 903–903. 35 indexed citations
7.
Fernández‐Irigoyen, Joaquín, Enrique Santamaría, Rosa Guarch, et al.. (2020). Absence of Nuclear p16 Is a Diagnostic and Independent Prognostic Biomarker in Squamous Cell Carcinoma of the Cervix. International Journal of Molecular Sciences. 21(6). 2125–2125. 14 indexed citations
8.
Blanco‐Luquin, Idoia, Paola Navarrete, David Guerrero‐Setas, et al.. (2019). Radiopotentiation of enzalutamide over human prostate cancer cells as assessed by real-time cell monitoring. Reports of Practical Oncology & Radiotherapy. 24(2). 221–226. 7 indexed citations
9.
Martín‐Sánchez, Esperanza, et al.. (2018). PO-388 Epigenetic silencing of ZNF177 by MIR-877–3 p could be involved in cervical cancer progression. ESMO Open. 3. A174–A174.
10.
Martín‐Sánchez, Esperanza, et al.. (2017). CDH22 hypermethylation is an independent prognostic biomarker in breast cancer. Clinical Epigenetics. 9(1). 7–7. 11 indexed citations
11.
Martín‐Sánchez, Esperanza, et al.. (2016). Gene promoter hypermethylation is found in sentinel lymph nodes of breast cancer patients, in samples identified as positive by one-step nucleic acid amplification of cytokeratin 19 mRNA. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 469(1). 51–59. 13 indexed citations
12.
Blanco‐Luquin, Idoia, Thérèse Liechtenstein, David Escors, et al.. (2015). Differential involvement ofRASSF2hypermethylation in breast cancer subtypes and their prognosis. Oncotarget. 6(27). 23944–23958. 19 indexed citations
13.
Blanco‐Luquin, Idoia, Berta Ibáñez, Berta Hernández, et al.. (2015). EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas. Oncotarget. 6(1). 368–380. 23 indexed citations
14.
Liechtenstein, Thérèse, Idoia Blanco‐Luquin, Cleo Goyvaerts, et al.. (2014). Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized usingex vivomyeloid-derived suppressor cells as a readout of therapeutic efficacy. OncoImmunology. 3(7). e945378–e945378. 35 indexed citations
15.
Liechtenstein, Thérèse, María Gato, Fabio Caliendo, et al.. (2014). A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. Oncotarget. 5(17). 7843–7857. 52 indexed citations
16.
Guerrero‐Setas, David, Laura Blanco, Koldo Cambra, et al.. (2013). RASSF2 hypermethylation is present and related to shorter survival in squamous cervical cancer. Modern Pathology. 26(8). 1111–1122. 29 indexed citations
17.
Escors, David, Thérèse Liechtenstein, Julia Katharina Schwarze, et al.. (2013). Assessing T-cell responses in anticancer immunotherapy. OncoImmunology. 2(10). e26148–e26148. 23 indexed citations
18.
Kochan, Grazyna, David Escors, Karine Breckpot, & David Guerrero‐Setas. (2013). Role of non-classical MHC class I molecules in cancer immunosuppression. OncoImmunology. 2(11). e26491–e26491. 126 indexed citations
19.
Liechtenstein, Thérèse, Christopher Bricogne, Alessio Lanna, et al.. (2013). Immune modulation by genetic modification of dendritic cells with lentiviral vectors. Virus Research. 176(1-2). 1–15. 18 indexed citations
20.
Córdoba, Alicia, et al.. (2012). Pleomorphic carcinoma of the breast with expression of macrophage markers: Report of two cases. Pathology International. 62(7). 491–495. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marina Gualco Breakdown of academic impact, for papers by Xianfeng Fang Breakdown of academic impact, for papers by Huda I. Atiya Breakdown of academic impact, for papers by Qitai Zhao Breakdown of academic impact, for papers by Sabrina Carpentier Breakdown of academic impact, for papers by Jovian Yu Breakdown of academic impact, for papers by Sangeeta Kakoti Breakdown of academic impact, for papers by Hussein Shehade Breakdown of academic impact, for papers by Emiri Nakazawa
Rankless by CCL
2026